Monte Rosa Therapeutics
GLUEPhase 2Monte Rosa Therapeutics is leveraging its proprietary QuEEN™ discovery engine to create a new class of small molecule medicines called molecular glue degraders, which harness the body's natural protein degradation machinery to eliminate specific disease-driving proteins. The company's lead program, MRT-2359, is a potent, selective degrader of GSPT1 and is being evaluated in a Phase 1/2 trial for MYC-driven solid tumors and lymphomas. With a strong leadership team, strategic partnerships, and a deep pipeline of preclinical programs, Monte Rosa aims to address significant unmet medical needs in oncology and beyond by targeting proteins that have historically been considered undruggable.
GLUE · Stock Price
Historical price data
AI Company Overview
Monte Rosa Therapeutics is leveraging its proprietary QuEEN™ discovery engine to create a new class of small molecule medicines called molecular glue degraders, which harness the body's natural protein degradation machinery to eliminate specific disease-driving proteins. The company's lead program, MRT-2359, is a potent, selective degrader of GSPT1 and is being evaluated in a Phase 1/2 trial for MYC-driven solid tumors and lymphomas. With a strong leadership team, strategic partnerships, and a deep pipeline of preclinical programs, Monte Rosa aims to address significant unmet medical needs in oncology and beyond by targeting proteins that have historically been considered undruggable.
Technology Platform
QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine, an integrated platform combining AI/ML, structural biology, and proteomics to rationally design molecular glue degraders that selectively eliminate disease-causing proteins.
Pipeline Snapshot
33 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + ... | NSCLC | Phase 1/2 |
| MRT-6160 + Placebo | Healthy Volunteers | Phase 1 |
| MRT-8102 + Placebo | Healthy Volunteers | Phase 1 |
Funding History
2Total raised: $281.3M
Opportunities
Risk Factors
Competitive Landscape
Monte Rosa competes in the targeted protein degradation space with companies like Nurix, Kymera, and C4 Therapeutics, as well as large pharma. Its key differentiation is its focus on discovering novel molecular glues (smaller, drug-like molecules) using its integrated QuEEN platform, as opposed to primarily developing larger PROTAC molecules or leveraging known glue interfaces.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile